NEW YORK (GenomeWeb) – Agilent Technologies announced today that it has signed a co-marketing agreement with Carlsbad, California-based Applied Spectral Imaging for fluorescent in situ hybridization (FISH) products.
Under the terms of the agreement, the firms will jointly market ASI's GenASIs imaging platforms with Agilent's FISH products, including the Dako Omnis instrument for automated sample processing. The agreement would provide pathology labs with the components to create a fully automated, end-to-end FISH workflow, the firms said in a statement.
Financial details of the deal were not disclosed.
"Difficulty of fluorescence-based molecular analysis has always been a major pain point for our customers," Herman Verrelst, VP and general manager of Agilent's genomics solutions and clinical applications divisions, said in a statement. "We anticipate that Agilent's broad portfolio of FISH reagents and instruments, and ASI's industry-leading computer-aided imaging solutions, will address such critical customer needs and enable laboratories to have a standardized, efficient, and high-quality FISH workflow."
The GenASIs platform can be used with any brightfield or fluorescence microscope and supports manual and automatic scanning.